The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2017 | Liquid biospy approaches for detecting MM and their optimization
It has become apparent in recent years that low levels of ciculating tumor DNA can be detected in multiple myeloma (MM) patients through liquid biopsies. In this interview, Suzanne Trudel, MD, MSc, FRCPC, of the Princess Margaret Hospital, Toronto, Canada, gives an overview of how this approach may be refined in the coming years, so that it may replace the more invasive and painful bone marrow biopsy, in both clinical and research contexts.
